Cécile Demur

Institut universitaire du cancer de Toulouse Oncopole — France

Medicine · Health Sciences

35h-index4.6kcitations127works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(62), Chronic Myeloid Leukemia Treatments(14), Acute Lymphoblastic Leukemia research(12), Chronic Lymphocytic Leukemia Research(11), Myeloproliferative Neoplasms: Diagnosis and Treatment(9)

Publications127 total

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With <scp>FLT3</scp> ‐Mutated <scp>AML</scp> : A <scp>FILO</scp> ‐ <scp>DATAML</scp> ‐ <scp>PETHEMA</scp> Real‐World Study
American Journal of Hematology·2026Open Access
Structural and functional consequences of IL33 and IL1RL1 coding variants on IL-33/ST2 signaling
2026Open Access
Supplementary Figure 1 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Supplementary Figure 3 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Supplementary Figure 1 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Supplementary Figure 4 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Supplementary Figure 5 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Data from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023· 1 citedOpen Access
Supplementary Figure 3 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Supplementary Figure 5 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Supplementary Figure 2 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Supplementary Figure 4 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Supplementary Figure 2 from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Data from Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
2023Open Access
Dendrogenin A drives LXR to trigger lethal autophagy in cancers
Nature Communications·2017· 101 citedOpen Access
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients
Haematologica·2017· 86 citedOpen Access
Abstract A27: Long noncoding RNA expression in cytogenetically normal acute myeloid leukemia identifies a distinct signature associated with NPM1 mutations
Cancer Research·2016
Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML
Blood·2015
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
Oncotarget·2015· 25 citedOpen Access
Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia
Hematological Oncology·2015· 17 cited
page 1 of 7Next →

Frequent Co-authors

Christian Récher(22), Bernard Payrastre(12), Véronique Mansat‐De Mas(11), Guy Laurent(10), Éric Delabesse(10), Stéphane Manenti(9), Claire Racaud‐Sultan(8), Nicole Dastugue(8), François Vergez(7), Sarah Bertoli(6), Christine Didier(6), Bernard Ducommun(6), Françoise Huguet(5), Naïs Prade-Houdellier(5), Véronique Mansat‐De Mas(5), Pierre Brousset(5), Cédric Dos Santos(4), Jean‐Emmanuel Sarry(4), Loïc Ysebaert(4), Fabienne de Toni(4)